Low-dose GHR [growth hormone replacement] improves body composition and QoL [quality of life] as early as 1 month after commencement and the beneficial effects continue at 3 months. Most importantly, these changes occur in the absence of side-effects. We therefore suggest the use of low-dose GH therapy, maintaining IGF-I between the median and upper end of the age-related reference range, for the treatment of AGHD [Adult Growth Hormone Deficiency].